In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
A renowned cardiac surgeon, Head of Clinic for Cardiac Surgery, Bialystok Medical University, Poland. He is a member of the European Association for Cardio-Thoracic Surgery, with experience obtained in Italy and Germany. He specializes, among other areas, in heart valve repair.
